Skip to Content
COVID-19 Resources
Cancer Imaging Program (CIP)
Contact CIP
Show menu
Search this site
Last Updated: 03/24/21

Current CIP Initiatives

This page lists current opportunities from CIP.

For information about the funding process, go to Mechanisms or Guidelines.

The NCI’s Division of Extramural Activities provides information about newly approved concepts, which may become RFAs and PAs. Check the Concepts Cleared at the NCI Board of Scientific Advisors Meeting web site for the earliest possible information about future initiatives.

CIP Scientific Contact Link to Initiative
Darrell Tata, Ph.D
Robert J. Nordstrom, Ph.D.
NOT-CA-21-032: Notice of Special Interest (NOSI): Translation of Quantitative Imaging tools and Methods for the Academic Industrial Partnership
Huiming Zhang, Ph.D. PAR-18-841: Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)
Christopher Hartshorn, Ph.D. PAR-20-155: Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
Christopher Hartshorn, Ph.D.
Piotr Grodzinski, Ph.D.
PAR-20-284: Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)
Lalitha Shankar, M.D., PhD. NOT-CA-21-028: Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers
Piotr Grodzinski, Ph.D. PAR-20-116: Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
Pushpa Tandon, Ph.D. PAR-20-295: Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)
Lalitha Shankar, M.D., Ph.D. PA-19-112: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01 Clinical Trial Optional)
Lalitha Shankar, M.D., Ph.D. PA-19-111: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21 Clinical Trial Optional)
Huiming Zhang, Ph.D. PAR-18-841: Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)
Chiayeng Wang, Ph.D. PAR-19-363: Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
Michael McDonald, M.D., Ph.D. PAR-21-033: National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
Christopher Hartshorn, Ph.D. PAR-21-166: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 Clinical Trial Not Allowed)
Christopher Hartshorn, Ph.D. PAR-21-206: Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 Clinical Trial Optional)
Piotr Grodzinski, Ph.D. PAR-20-116: Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)

Scientific Contact Link to Initiative
Chiayeng Wang, Ph.D. PAR-20-277: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
Chiayeng Wang, Ph.D. PAR-20-276: Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)